Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer’s

作者：Tanya Song, Yunfei Wang, Bret Silverglate, George T. Grossberg · 发表于：Expert Opinion on Drug Metabolism & Toxicology · 年份：2024 · DOI：10.1080/17425255.2024.2357637 · 被引用次数：9 · 研究领域：Alzheimer's disease research and treatments、Dementia and Cognitive Impairment Research、Multiple Sclerosis Research Studies

INTRODUCTION: Donanemab is a humanized monoclonal antibody that significantly reduces cerebral amyloid plaques in Alzheimer's Disease (AD). It can delay disease progression and cognitive decline, making it one of the most promising disease-modifying treatments in the current treatment landscape. AREAS COVERED: This paper covers the current literature available on pharmacokinetics, pharmacodynamics, safety, and tolerability of donanemab. Publications from PubMed and Google were reviewed. A summary of regulatory approvals and current clinical data is also provided. EXPERT OPINION/COMMENTARY: Donanemab as a therapy for AD has more effective disease-modifying effects compared to lecanemab. Donanemab appears generally well-tolerated; however, it may have higher rates of severe side effects, such as amyloid-related imaging abnormalities (ARIA), that could lead to death. Guidelines for frequency of MRI monitoring for ARIA/safety are pending but will be integral to determining its use. Despite some limitations, donanemab is expected to receive FDA approval, giving clinicians access to another disease-modifying drug. Overall, more data is needed about donanemab, especially relating to safety, efficacy, cost, and integration with other treatments, but its development signifies progress in AD treatment.